An ongoing clinical trial (NCT03935893) is studying adoptive transfer of TILs for advanced solid tumors including sarcoma, and another (NCT04052334) is evaluating the safety and feasibility of TIL treatment with high-dose IL-2 in patients with soft tissue sarcoma (30, 31). The gene discussed is IL2; the disease is soft tissue sarcoma.